Prabhudas Lilladher has issued a 'BUY' rating on Anthem Biosciences with a target price of ₹755 per share, as reported by Moneycontrol. The brokerage initiated coverage on the stock with this recommendation in its research report dated March 30, 2026. The target price implies approximately 16% upside potential from current market levels, positioning the stock as a growth opportunity in the pharmaceutical sector.
According to Prabhudas Lilladher's analysis, the company is forecast to deliver strong growth metrics over the FY26-28E period. The brokerage projects Revenue/EBITDA/PAT CAGR of approximately 21%/22%/18% respectively, driven by robust operational performance. Key growth drivers include 23% growth in CDMO services, ~11% growth in CRO services, and ~14% growth in specialty ingredients segments. As reported by Moneycontrol, Anthem Biosciences is positioned as one of the fastest growing Indian CRDMOs in the market.
The research highlights Anthem Biosciences' strong growth visibility supported by a comprehensive pipeline spanning discovery to late-stage development phases. The company maintains a commercial portfolio alongside its development programs. According to the report, Anthem is planning ₹10-12 billion in capex to expand capacity, with the majority of funding coming through internal accruals. The specialty ingredients business is expected to benefit significantly from GLP-1 API ramp-up anticipated from H2CY26.
At current market price, Anthem Biosciences is trading at approximately 30x EV/EBITDA and 44x P/E on FY28E estimates, as reported by Moneycontrol. Prabhudas Lilladher values the company at 50x P/E on FY28E, which aligns with industry divisions. The brokerage expects healthy demand for commercialized molecules, supported by the ramp-up of recently launched molecules and potential commercialization of late-stage programs, positioning the stock favorably for continued growth in the pharmaceutical sector.
